CIK 0001806310
- Non-accelerated filer
- Smaller reporting company
Taysha Gene Therapies, Inc.
Sign in to watch- Ticker
- TSHA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 843199512
- Phone
- +1 214-612-0000
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
- 4 Open-market buy Director bought 10,000 shares at $8.01 ($80,100)
- 4 Open-market buy Director bought 3,000 shares at $7.78 ($23,340)
- 4 Open-market buy President and CEO bought 42,518 shares at an average $12.44 ($529,102)
- 4 Open-market buy Director bought 2,202 shares at $13.19 ($29,044)
- 4 Open-market buy Director bought 20,000 shares at $12.54 ($250,800)
- 4 Open-market sale Chief Financial Officer sold 33,000 shares at an average $16.88 ($557,023)
- 4 Open-market sale CMO and Head of R&D sold 79,000 shares at an average $22.63 ($1,787,936)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Director bought 1,170 shares at $22.35 ($26,150)
- 4 Open-market buy Director bought 12,000 shares at $20.98 ($251,760)
- 5 Insider Annual Insider Trading Report
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 5 of 6 · 120 filings